International Drug Names
R05DA11 ( ) WHO
(4b S,8a S,9 S)-3,11-Dimethyl-6,7,8,8a,9,10-hexahydro-5 H-9,4b-(epiminoethano)phenanthrene
Chemical and physical data
C 18 H 25 N
Molar mass 255.398 g/mol
3D model (
Dimemorfan ( INN) (or dimemorphan) (brand names Astomin, Dastosirr, Tusben), or dimemorfan phosphate ( JAN), also known as 3,17-dimethylmorphinan, is an antitussive (cough suppressant) of the morphinan family that is widely used in Japan and is also marketed in Spain and Italy.    It was developed by  Yamanouchi Pharmaceutical (now Astellas Pharma) and introduced in Japan in 1975. Dimemorfan is an  analogue of dextromethorphan (DXM) and its active metabolite dextrorphan (DXO), and similarly to them, acts as a potent agonist of the σ (K 1 receptor i = 151 nM).  However, unlike DXM and DXO, it does not act significantly as an  NMDA receptor antagonist, and for this reason, lacks dissociative effects, thereby having reduced side effects and abuse potential in comparison.  Similarly to DXM and DXO, dimemorfan has only relatively low  affinity for the σ (K 2 receptor i = 4421 nM). 
See also [ edit ]
References [ edit ]
^ J. Elks (14 November 2014). . Springer. pp. 427–. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies ISBN 978-1-4757-2085-3.
^ Eduardo Bruera; Irene Higginson; Charles F. von Gunten; Tatsuya Morita (15 January 2015). . CRC Press. pp. 677–. Textbook of Palliative Medicine and Supportive Care, Second Edition ISBN 978-1-4441-3526-8.
^ a b Ida, Hisashi (1997). "The nonnarcotic antitussive drug dimemorfan: a review". Clinical Therapeutics. 19 (2): 215–231. doi: 10.1016/S0149-2918(97)80111-7. ISSN 0149-2918.
^ Lora L. Armstrong; Morton P. Goldman (1 January 2005). . Lexi-Comp. Lexi-Comp's Drug Information Handbook International: With Canadian and International Drug Monographs ISBN 978-1-59195-110-0.
^ Maurice, Tangui; Su, Tsung-Ping (2009). "The pharmacology of sigma-1 receptors". Pharmacology & Therapeutics. 124 (2): 195–206. doi: 10.1016/j.pharmthera.2009.07.001. ISSN 0163-7258.
^ a b Luis M. Botana; Mabel Loza (20 April 2012). . John Wiley & Sons. pp. 234–. Therapeutic Targets: Modulation, Inhibition, and Activation ISBN 978-1-118-18552-0.
^ Chou, Yueh-Ching; Liao, Jyh-Fei; Chang, Wan-Ya; Lin, Ming-Fang; Chen, Chieh-Fu (1999). "Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan". Brain Research. 821 (2): 516–519. doi: 10.1016/S0006-8993(99)01125-7. ISSN 0006-8993.
^ Shin, Eun-Joo; Nah, Seung-Yeol; Kim, Won-Ki; Ko, Kwang Ho; Jhoo, Wang-Kee; Lim, Yong-Kwang; Cha, Joo Young; Chen, Chieh-Fu; Kim, Hyoung-Chun (2005). "The dextromethorphan analog dimemorfan attenuates kainate-induced seizuresvia σ1receptor activation: comparison with the effects of dextromethorphan". British Journal of Pharmacology. 144 (7): 908–918. doi: 10.1038/sj.bjp.0705998. ISSN 0007-1188.